Загрузка...
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...
Сохранить в:
| Опубликовано в: : | Endocr Connect |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Bioscientifica Ltd
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7576644/ https://ncbi.nlm.nih.gov/pubmed/33064663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-20-0342 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|